Search
Briacell Therapeutics Corp
BCTXAdd to Watchlist
3.950USD
+0.680+20.80%
Close 11-06 16:00（ET）
34.37MMarket Cap
LossP/E TTM
BCTX Analyst Recommendation Trends
In the current month, BCTX has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BCTX average Analyst price target in the last month is 40.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
BCTX Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-4.84
-2.74
-2.09
Actual
-2.58
-0.99
-1.50
Surprise
+46.75%
+63.94%
+28.24%
FAQs
What is the analyst rating for Briacell Therapeutics Corp?
Based on the ratings of Briacell Therapeutics Corp's stock from 0 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.